⟵ Go Back

Patent protection for NeuroShield granted in the US

August 2019

Monarch Bioimplants has been granted a US patent (# 10,328,096) to protect its advanced chitosan- based technology for use in the prevention and/or treatment of impotence in patients undergoing radical prostatectomy. This milestone is an important pre-requisite for the launch of the company's flagship product NeuroShield in the US market which is planned in September 2019.
Following the recent FDA clearance of NeuroShield in the US, its protection by a US patent allows to enter this large medical device market with a sustainable commercialization strategy. Moreover, the company is continuing to expand its patent portfolio, and a new patent application protecting innovative structures to further enhance the potency recovery has recently been submitted.